Related Experiment Video

Updated: Oct 1, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Development and evaluation of pneumococcal conjugate vaccines: clinical trials and control tests

Lucia H Lee1, Chi-Jen Lee, Carl E Frasch

  • 1Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852-1448, USA.

Critical Reviews in Microbiology
|May 11, 2002
PubMed

Insights

Pneumococcal conjugate vaccines significantly improve infant immunization, preventing serious infections like pneumonia and meningitis. Research reviews current vaccines and explores future strategies to combat antibiotic resistance.

Area of Science:

  • Immunology
  • Microbiology
  • Vaccinology

Background:

  • Streptococcus pneumoniae causes severe pneumonia, meningitis, and otitis media, particularly in vulnerable populations.
  • Increasing antibiotic resistance necessitates alternative prevention methods like vaccination.
  • Pneumococcal conjugate vaccines (PCVs) have proven effective in preventing disease, especially in children.

Purpose of the Study:

  • To review clinical trials of current multivalent pneumococcal conjugate vaccines.
  • To identify potential carrier proteins for future PCV development.
  • To discuss regulatory and quality control aspects for new vaccine licensure and alternative strategies.

Main Methods:

  • Review of clinical trial data for existing and emerging pneumococcal conjugate vaccines.
  • Analysis of carrier protein efficacy in vaccine development.
  • Examination of regulatory pathways and quality control measures for vaccine approval.

Main Results:

  • Multivalent PCVs demonstrate enhanced immunogenicity and efficacy in infants and children compared to polysaccharide vaccines.
  • Specific carrier proteins have shown promise for improving immune responses in future vaccine candidates.
  • Established clinical trial and quality control frameworks support the licensure of new vaccines.

Conclusions:

  • Pneumococcal conjugate vaccines are crucial for preventing invasive pneumococcal disease globally.
  • Ongoing research into novel carrier proteins and vaccine strategies is vital to address evolving resistance patterns.
  • Robust clinical evaluation and quality control are essential for the successful development and deployment of new pneumococcal vaccines.

More Related Videos

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...